Skip to main content

Day: June 29, 2020

OptimizeRx Engages UHY as New Independent Registered Public Accounting Firm

ROCHESTER, Mich., June 29, 2020 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, payers, providers and patients, has engaged UHY LLP as its new auditor, effective Monday, June 22. There were no accounting disagreements or issues with the prior auditor.UHY has 21 offices nationwide, with several local to the company’s headquarters in Southeastern Michigan. It serves companies ranging from mid-sized to the Fortune 500, throughout the U.S. and around the globe.“We are excited to welcome UHY as our new auditor,” said OptimizeRx CFO, Doug Baker. “We anticipate using an auditor with local offices to have a significant positive impact on the efficiency of our audit, including the elimination of travel, especially in the new COVID-19 world.”For additional details,...

Continue reading

Titan Mining Announces Results of the Annual General Meeting of Shareholders

VANCOUVER, British Columbia, June 29, 2020 (GLOBE NEWSWIRE) — Titan Mining Corporation (TSX:TI) (“Titan” or the “Company”) announces that, at the annual general meeting of shareholders held on June 26, 2020, shareholders voted in favour of setting the number of directors at eight, and each of the eight nominees listed in the management information circular dated May 14, 2020, were elected as directors of the Company.A summary of the results for the election of Titan’s Board of Directors is provided below:Shareholders also voted in favour of the re-appointment of Ernst & Young, LLP, Chartered Accountants as auditor for the ensuing year, and the directors were authorized to set the auditor’s remuneration.About Titan Mining CorporationTitan is an Augusta Group company which produces zinc concentrate at its 100%-owned Empire State...

Continue reading

FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer

Phesgo offers faster administration of Perjeta and Herceptin under the skin in just minutes, compared to hours with standard intravenous administrationData showed that 85% of patients preferred Phesgo compared to standard intravenous administration             Basel, 29 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.Attachment29062020_MR_PHESGO

Continue reading

Crossject : Résultat des votes de l’AG Mixte du 25 juin 2020

Communiqué de Presse Crossject : Résultat des votes de l’Assemblée Générale Mixte du 25 juin 2020Dijon, 29 juin 2020CROSSJECT (ISIN: FR0011716265; Mnémo: ALCJ), « specialty pharma » qui développe un portefeuille de médicaments combinés innovants dédiés aux situations d’urgence, a tenu son Assemblée Générale Mixte Annuelle à huis-clos le 25 juin 2020 au siège social, sous la présidence de M. Philippe Monnot, président du Conseil de Surveillance.Le bureau était également composé de deux scrutateurs désignés par le Directoire : Mme Castano et  M. Garret. M. Philippe Lafitte a été désigné en qualité de secrétaire du bureau.Le bureau a constaté, au vu des votes par correspondance et des pouvoirs reçus, que les actionnaires participants représentaient 33,70 % des actions formant le capital et ayant le droit de vote et donc que l’Assemblée était...

Continue reading

Hagar hf. árshlutauppgjör Q1 // mars 2020 – maí 2020

Árshlutareikningur Haga hf. fyrir fyrsta ársfjórðung 2020/21 var samþykktur af stjórn og forstjóra félagsins á stjórnarfundi þann 29. júní 2020. Reikningurinn er fyrir tímabilið 1. mars 2020 til 31. maí 2020. Árshlutareikningurinn hefur að geyma samstæðureikning félagsins og dótturfélaga þess og er hann gerður í samræmi við alþjóðlega reikningsskilastaðla (IFRS). Reikningurinn hefur hvorki verið kannaður né endurskoðaður af endurskoðendum félagsins, PricewaterhouseCoopers ehf.Helstu niðurstöður á fyrstu þremur mánuðum rekstrarársins:Tap tímabilsins eftir skatta nam 96 millj. kr. eða 0,3% af veltu.Tap á hlut var 0,08 kr.Vörusala tímabilsins nam 28.241 millj. kr.Framlegð tímabilsins var 20,6%.Hagnaður fyrir afskriftir, fjármagnsliði og skatta (EBITDA) nam 1.297 millj. kr.Heildareignir samstæðunnar námu 64.039 millj. kr. í lok tímabilsins.Handbært...

Continue reading

Aegion Corporation Awarded $6 Million Wastewater Rehabilitation Contract from the City of Newton, Massachusetts

ST. LOUIS, June 29, 2020 (GLOBE NEWSWIRE) — Aegion Corporation (NASDAQ:AEGN) today announced that its subsidiary, Insituform Technologies, LLC, has been awarded a contract valued at $6 million from the City of Newton, Massachusetts, for the rehabilitation of its wastewater systems.Insituform will perform a number of trenchless services on the project, including 70,000 linear feet of 6-inch to 12-inch cured-in-place pipe (CIPP) lining, lateral lining, sectional liners and geopolymer manhole rehabilitation.Insituform has been installing CIPP lining for Newton since 2007 and has won more than $12 million in contracts since 2017. The project is recently underway and is expected to be fully completed by June 2021.About Aegion Corporation (NASDAQ:  AEGN)Aegion combines innovative technologies with market-leading expertise to maintain,...

Continue reading

Síminn hf.: Samningur við Arion banka um viðskiptavakt

Síminn hf. hefur gert nýjan samning við Arion banka um viðskiptavakt. Arion Banki mun dag hvern leggja fram kaup- og sölutilboð í hlutabréf félagsins í viðskiptakerfi Kauphallarinnar. Tilgangurinn með viðskiptavaktinni er að efla viðskipti með hlutabréf félagsins á Nasdaq OMX Iceland í því skyni að seljanleiki hlutabréfa félagsins aukist, markaðsvirði skapist og verðmyndun hlutabréfanna verði með skilvirkum og gagnsæjum hætti.Fjárhæð kaup- og sölutilboða skal vera að lágmarki 2.500.000 bréf að nafnvirði á gengi sem Arion banki ákveður, þó ekki með meira en 3% fráviki frá síðasta viðskiptaverði. Hámarksmunur kaup- og sölutilboða er 1,5%. Eigi Arion banki viðskipti með bréf félagsins fyrir 80 m.kr. að markaðsvirði eða meira í sjálfvirkri pörun innan dags, sem fer um veltubók Arion banka, falla niður skyldur um hámarksmun kaup- og sölutilboða...

Continue reading

ERYTECH gibt Abstimmungsergebnisse der Jahreshauptversammlung vom 26. Juni 2020 bekannt

LYON, Frankreich und CAMBRIDGE, Mass., June 29, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP) gibt bekannt, dass die Jahreshauptversammlung 2020 am Freitag, den 26. Juni 2020 in Lyon abgehalten wurde.Bei der Versammlung wurden alle vom Vorstand empfohlenen Beschlüsse angenommen, darunter:– Genehmigung des Jahresabschlusses und des konsolidierten Jahresabschlusses für das am 31. Dezember 2019 abgelaufene Jahr;– Aufteilung der Jahresfinanzergebnisse;– Genehmigung des Sonderberichts der Wirtschaftsprüfer zu rechtlich regulierten Vereinbarungen mit und Verpflichtungen gegenüber verbundenen Parteien;– Genehmigung der an Gil Beyen und Jean-Paul Kress gezahlten oder zugeteilten Gesamtvergütungen und Leistungen für das am 31. Dezember 2019 abgelaufene Jahr;– Genehmigung der Vergütungsrichtlinie für höhere...

Continue reading

ERYTECH riporta i risultati delle votazioni dell’Assemblea Generale Annuale tenutasi il 26 giugno 2020

LIONE, Francia e CAMBRIDGE, Mass., June 29, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP) ha annunciato che l’Assemblea Generale Annuale 2020 si è tenuta a Lione venerdì 26 giugno 2020.Nel corso della riunione sono state adottate tutte le delibere per le quali il Consiglio di Amministrazione ha raccomandato un voto favorevole, tra cui:– Approvazione del bilancio annuale e del bilancio consolidato per l’esercizio chiuso al 31 dicembre 2019;– Allocazione dei risultati dell’esercizio;– Approvazione della relazione speciale dei sindaci su accordi e impegni regolamentati con parti correlate;– Approvazione degli elementi di remunerazione totale e benefit corrisposti o assegnati per l’esercizio chiuso al 31 dicembre 2019 a Gil BEYEN e Jean-Paul KRESS;– Approvazione della politica di...

Continue reading

The RPAR Risk Parity ETF Surpasses $500 AUM Milestone; Recognized for Growth and Innovation

LOS ANGELES, June 29, 2020 (GLOBE NEWSWIRE) —  Advanced Research Investment Solutions (ARIS), the Los Angeles-based wealth management and consulting firm with $12 billion in assets under management (AUM), today announced the RPAR Risk Parity ETF (NYSE: RPAR) has surpassed $500 million in AUM, just 6 months following its launch in December 2019. The fund seeks to provide investors with low-cost and tax-efficient passive exposure to a risk parity investment strategy. According to Yahoo! Finance, RPAR is one of fastest growing ETFs of 20201 and has been nominated for Newcomer Alternative ETF of the Year by Fund Intelligence2. It was also recently named the Best New Alternatives ETF of the Year by etf.com3.

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.